Development and evaluation of novel recombinant adenovirus-based vaccine candidates for infectious bronchitis virus and <i>Mycoplasma gallisepticum</i> in chickens

Zhang, Dongchao; Long, Yuqing; Li, Meng; Gong, Jicheng; Li, Xiaohui; Lin, Jing; Meng, Jiali; KeKe, Gao; Zhao, Ruili; Jin, Tao

doi:10.1080/03079457.2017.1403009

Cited by 15 publications

(14 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recombinant adenovirus was constructed containing the TM-1 protein of MG (pBH-S1-TM-1-EGFP) and S1 spike glycoprotein of infectious bronchitis virus. The recombinant bivalent pBH-S1-TM-1-EGFP adenovirus construct vaccine provides potential protective effects against bronchitis and MG infection ( Zhang et al., 2018 ). Therefore, preventive measures against MG infection and other respiratory pathogens must take into account by vaccination and/or antimicrobial agents.…”

Section: Challengesmentioning

confidence: 99%

“…Nonpathogenic and attenuated bacteria may be used as vectors, but nonpathogenic species are preferred ( Liljeqvist and Stahl, 1999 ). The development of recombinant vaccines by cloning and identification of important MG surface antigens and colonization factor, development of expression and transformation strategies bewitch the interest of scientist ( Zhang et al., 2010 , 2018 ; Shil et al., 2011 ). Gene transfer is accomplished in mycoplasma species by electroporation ( Liu et al., 2000 ; Pour-El et al., 2002 ; Mudahi-Orenstein et al., 2003 ) and Enterococcus faecalis –mediated conjugation ( Ruffin et al., 2002 ).…”

Section: Mg Vaccine Candidatesmentioning

confidence: 99%

See 1 more Smart Citation

Current status of vaccine research, development, and challenges of vaccines for Mycoplasma gallisepticum

Ishfaq

Khan

et al. 2020

Poultry Science

View full text Add to dashboard Cite

Mycoplasma gallisepticum ( MG ) is an important avian pathogen that causes significant economic losses in the poultry industry. Surprisingly, the limited protection and adverse reactions caused by the vaccines, including live vaccines, bacterin-based (killed) vaccines, and recombinant viral vaccines is still a major concern. Mycoplasma gallisepticum strains vary in infectivity and virulence and infection may sometimes unapparent and goes undetected. Although extensive research has been carried out on the biology of this pathogen, information is lacking about the type of immune response that confers protection and selection of appropriate protective antigens and adjuvants. Regardless of numerous efforts focused on the development of safe and effective vaccine for the control of MG, the use of modern DNA vaccine technology selected in silico approaches for the use of conserved recombinant proteins may be a better choice for the preparation of novel effective vaccines. More research is needed to characterize and elucidate MG products modulating MG-host interactions. These products could be used as a reference for the preparation and development of vaccines to control MG infections in poultry flocks.

show abstract

Section: Challengesmentioning

confidence: 99%

Section: Mg Vaccine Candidatesmentioning

confidence: 99%

Current status of vaccine research, development, and challenges of vaccines for Mycoplasma gallisepticum

Ishfaq

Khan

et al. 2020

Poultry Science

View full text Add to dashboard Cite

show abstract

“…Numerous attempts have been made for vaccine development against Mycoplasma microorganisms, exploring DNA, proteins, or capsular polysaccharides for effective control. Novel approaches include recombinant protein or DNA vaccines [117,118], subunit vaccines [119,120], nanoparticle-based vaccines [121,122], plant-based or edible vaccines [123,124], and cytokine or TLR-based vaccines [125,126,127].…”

Section: Clues From Other Novel Vaccinesmentioning

confidence: 99%

“…Hence, it can also be investigated as a vaccine candidate. Recombinant vaccine constructs using the TM-1 protein of Mycoplasma gallisepticum (pBH-S1-TM-1-EGFP) have been studied by Zhang et al [118].…”

Section: Clues From Other Novel Vaccinesmentioning

confidence: 99%

Novel Candidates for Vaccine Development Against Mycoplasma Capricolum Subspecies Capripneumoniae (Mccp)—Current Knowledge and Future Prospects

et al. 2019

View full text Add to dashboard Cite

Exploration of novel candidates for vaccine development against Mycoplasma capricolum subspecies capripneumoniae (Mccp), the causative agent of contagious caprine pleuropneumonia (CCPP), has recently gained immense importance due to both the increased number of outbreaks and the alarming risk of transboundary spread of disease. Treatment by antibiotics as the only therapeutic strategy is not a viable option due to pathogen persistence, economic issues, and concerns of antibiotic resistance. Therefore, prophylactics or vaccines are becoming important under the current scenario. For quite some time inactivated, killed, or attenuated vaccines proved to be beneficial and provided good immunity up to a year. However, their adverse effects and requirement for larger doses led to the need for production of large quantities of Mccp. This is challenging because the required culture medium is costly and Mycoplasma growth is fastidious and slow. Furthermore, quality control is always an issue with such vaccines. Currently, novel candidate antigens including capsular polysaccharides (CPS), proteins, enzymes, and genes are being evaluated for potential use as vaccines. These have shown potential immunogenicity with promising results in eliciting protective immune responses. Being easy to produce, specific, effective and free from side effects, these novel vaccine candidates can revolutionize vaccination against CCPP. Use of novel proteomic approaches, including sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), two-dimensional gel electrophoresis, immunoblotting, matrix-assisted laser desorption/ionization-time-of-flight (MALDI-TOF) mass spectrometry, tandem mass spectroscopy, fast protein liquid chromatography (FPLC), bioinformatics, computerized simulation and genomic approaches, including multilocus sequence analysis, next-generation sequencing, basic local alignment search tool (BLAST), gene expression, and recombinant expression, will further enable recognition of ideal antigenic proteins and virulence genes with vaccination potential.

show abstract

“…IBV belongs to the genus Coronavirus, family Coronaviridae, of the order Nidovirales (Mayo and Pringle 1998). The IBV genome consists of a single-stranded positive-sense RNA that encodes four structural proteins [spike (S), membrane (M), envelope (E), and nucleoprotein (N)] (Feng et al 2017;Zhang et al 2018Zhang et al , 2019. IBV primarily infects the respiratory tract, kidneys, and reproductive system of poultry, which can cause difficulty breathing and an enlargement of the kidneys (Cavanagh 2007).…”

Section: Introductionmentioning

confidence: 99%

The Efficacy of a Live Attenuated TW I-Type Infectious Bronchitis Virus Vaccine Candidate

Zhang

Chen

et al. 2021

Virol. Sin.

View full text Add to dashboard Cite

Infectious bronchitis (IB) is a highly contagious avian disease caused by infection with infectious bronchitis virus (IBV), which seriously affects the development of the global poultry industry. The distribution of TW I-type IBV in China has increased in recent years, becoming a widespread genotype. We previously isolated a TW I-type IBV strain termed CK/ CH/GD/GZ14 in 2014, but its pathogenicity and possibility for vaccine development were not explored. Therefore, this research aimed to develop a live-attenuated virus vaccine based on the CK/CH/GD/GZ14 strain. The wild type IBV CK/ CH/GD/GZ14 strain was serially passaged in SPF embryos for 145 generations. The morbidity and mortality rate of wildtype strain in 14 day-old chickens is 100% and 80% respectively, while the morbidity rate in the attenuated strain was 20% in the 95th and 105th generations and there was no death. Histopathological observations showed that the pathogenicity of the 95th and 105th generations in chickens was significantly weakened. Further challenge experiments confirmed that the attenuated CK/CH/GD/GZ14 strain in the 95th and 105th generations could resist CK/CH/GD/GZ14 (5th generation) infection and the protection rate was 80%. Tracheal cilia stagnation, virus shedding, and viral load experiments confirmed that the 95th and 105th generations provide good immune protection in chickens, and the immunogenicity of the 105th generation is better than that of the 95th generation. These data suggest that the attenuated CK/CH/GD/GZ14 strain in the 105th generation may be applied as a vaccine candidate against TW I-type IBV.

show abstract

Development and evaluation of novel recombinant adenovirus-based vaccine candidates for infectious bronchitis virus and Mycoplasma gallisepticum in chickens

Cited by 15 publications

References 63 publications

Current status of vaccine research, development, and challenges of vaccines for Mycoplasma gallisepticum

Current status of vaccine research, development, and challenges of vaccines for Mycoplasma gallisepticum

Novel Candidates for Vaccine Development Against Mycoplasma Capricolum Subspecies Capripneumoniae (Mccp)—Current Knowledge and Future Prospects

The Efficacy of a Live Attenuated TW I-Type Infectious Bronchitis Virus Vaccine Candidate

Contact Info

Product

Resources

About